Relief Therapeutics Reports 2024 Half-Year Results, Provides Business Update

Relief Therapeutics Reports 2024 Half-Year Results, Provides Business Update

• Results from investigator-initiated RLF-TD011 trial for EB wound treatment expected in the coming weeks
• RLF-OD032 pilot PK study progressing with potential NDA filing mid to late 2025
• Streamlined operations and cash reserves of CHF 15.1 million are expected to provide funding until at least 2026

GENEVA (30 AUG. 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company focused on delivering innovative treatment options for selected specialty, unmet and rare diseases, today reported financial results for the half year ended June 30, 2024 and provided a business update.

Relief provided updates on its key development programs and strategic initiatives, including RLF-TD011, a topical hypochlorous acid spray designed for the treatment of epidermolysis bullosa (EB), and RLF-OD032, a novel liquid formulation of sapropterin dihydrochloride for the treatment of phenylketonuria (PKU).

The company reported significant financial improvements in the first half of 2024, with revenue up 85% and operating expenses down 45%, driven by strategic reorientation and cost-saving initiatives. However, investments in R&D were stable. As the company remains debt-free, it expects its cash reserves of CHF 15.1 million as of August 30, 2024 and expected revenue to finance operations until at least 2026.

The Relief 2024 half-year report is available on the Company website.

ABOUT SCAM
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to improve the lives of patients with certain specialty and rare diseases. Relief’s portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies, and a focused clinical development pipeline consisting of risk-mitigated assets focused on three core therapeutic areas: rare skin diseases, rare metabolic disorders and rare respiratory diseases. In addition, Relief is commercializing several legacy products through licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Financial Director
(email address)

INDEMNIFICATION
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including the ability to achieve its business, development and commercial goals, and other factors that may cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief’s filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief’s filings with the SEC are available in the SEC EDGAR database at www.sec.gov. Relief assumes no obligation to update the information contained herein, which speaks only as of the date hereof.